Rafferty Asset Management’s Nurix Therapeutics NRIX Stock Holding History
Bought
Maintained
Sold
Other funds holding NRIX
BBA
Rafferty Asset Management's NRIX Position: Q3 2026 in Review
Rafferty Asset Management increased its Nurix Therapeutics (NRIX) stake by 39% in Q3 2026, buying an estimated $668K and bringing the position to 95,171 shares worth $2.26M. The position accounts for 0.01% of the portfolio, ranked #595.
Rafferty Asset Management first reported a position in NRIX in Q1 2021 and has held it in 22 quarters since. The position peaked at $3.11M in Q1 2024. 234 funds tracked by Wall St. Rank hold NRIX as of Q3 2026.
- Rafferty Asset Management held 95,171 shares of Nurix Therapeutics worth $2.26M as of Q3 2026.
- Rafferty Asset Management bought 26,811 Nurix Therapeutics shares in Q3 2026, an estimated $668K.
- Nurix Therapeutics made up 0.01% of Rafferty Asset Management's portfolio in Q3 2026, its #595 holding.
- Rafferty Asset Management first reported a position in Nurix Therapeutics in Q1 2021 and has held it in 22 quarters since.
- Rafferty Asset Management's Nurix Therapeutics position peaked at $3.11M in Q1 2024.
- 234 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q3 2026.
Based on Rafferty Asset Management's 13F filing for Q3 2026, filed 13 Nov 2026.